MELQART ASSET MGMT: Form 8.3 - Dechra Phartmaceuticals PLC - Amendment
January 15 2024 - 10:40AM
UK Regulatory
TIDMDPH
AMENDMENT - this form replaces previous form released on 15/01/21 at 15:25 PM UK (London) time.
Correction made in Section 2, (a).
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1 KEY INFORMATION
(a) Full name of discloser: MELQART ASSET MANAGEMENT (UK) LTD
(b) Owner or controller of interests and short positions
disclosed, if different from 1(a): N/A
The naming of nominee or vehicle companies is insufficient. For
a trust, the trustee(s), settlor and beneficiaries must be
named.
(c) Name of offeror/offeree in relation to whose relevant
securities this form relates: Dechra Pharmaceuticals PLC
Use a separate form for each offeror/offeree
(d) If an exempt fund manager connected with an offeror/offeree,
state this and specify identity of offeror/offeree: N/A
(e) Date position held/dealing undertaken: 2024-01-12
For an opening position disclosure, state the latest practicable
date prior to the disclosure
(f) In addition to the company in 1(c) above, is the discloser
making disclosures in respect of any other party to the offer? No
If it is a cash offer or possible cash offer, state "N/A"
2 POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant
securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each
additional class of relevant security.
Interests and short positions in the relevant securities of the offeror or offeree to
(a) which the disclosure relates following the dealing (if any)
Class of relevant security: 1p ordinary
Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled:
(2) Cash-settled derivatives: 1,887,566 1.66%
(3) Stock-settled derivatives (including options)
and agreements to purchase/sell:
TOTAL: 1,887,566 1.66%
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to
purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which
subscription right exists:
Details, including nature of the rights concerned
and relevant percentages:
3 DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class
of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant Price per unit
security Purchase/sale Number of securities (GBp)
(b) Cash-settled derivative transactions
Price per
Class of relevant Product Number of reference unit
security description Nature of dealing securities (GBp)
e.g. opening/closing a
long/short position,
increasing/reducing a
e.g. CFD long/short position
decreasing a long
1p ordinary CFD position -38,760 3865 GBp
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Writing, Number of Option
Product purchasing, securities money
Class of description selling, to which Exercise paid/
relevant e.g. call varying option price per Expiry received
security option etc. relates unit Type date per unit
e.g. American,
European etc.
(ii) Exercise
Class of Exercising/
relevant exercised Number of Exercise price
security Product description against securities per unit
e.g. call option
(d) Other dealings (including subscribing for new securities)
Class of Price per unit
relevant (if
security Nature of dealing Details applicable)
e.g. subscription,
conversion
4 OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or
informal, relating to relevant securities which may be an inducement to deal or refrain from dealing
entered into by the person making the disclosure and any party to the offer or any person acting in
concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making
the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any
derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
None
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? No
Date of disclosure: 2024-01-15
Contact name: Ben Sharp
Telephone number: +44 (0)20 3826 4493
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation
to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20240115388349/en/
CONTACT:
Melqart Asset Management
SOURCE: Melqart Asset Management
Copyright Business Wire 2024
(END) Dow Jones Newswires
January 15, 2024 10:40 ET (15:40 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Dec 2024 to Jan 2025
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Jan 2024 to Jan 2025
